Suchergebnisse - "Ma, Xiwen"

PubPharm (4)

1

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Casasnovas, R. | Follows, G. | Zijlstra, J. | +30

2

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

enthalten in: Future oncology (London, England) | 2021

von Gounder, M. | Abdul Razak, A. | Gilligan, A. | +16

3

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

enthalten in: American journal of hematology | 2021

von Cornell, R. | Hari, P. | Tang, S. | +35

4

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

enthalten in: The Lancet. Haematology | 2020

von Kalakonda, N. | Maerevoet, M. | Cavallo, F. | +34

CommentIn: Lancet Haematol. 2020 Jul;7(7):e500-e501. - PMID 32589969

1
[1]